Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]
The start of a new year often brings renewed motivation, fresh habits, and ambitious weight loss goals
A healthcare professional can provide clarity
Below are the most relevant options for post-weight-loss laxity and Ozempic face concerns
Don't let enthusiasm push you up faster
Keeping a journal of vision changes can help us identify patterns and make better treatment decisions
US$ 22.69
US$ 20.19
US$ 28.31
US$ 29.76
